TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16767525

Group type: EXPERIMENTAL
Intervention: 250 microg daily nasal hPTH(1-34) spray for 3 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 500 microg daily nasal hPTH(1-34) spray for 3 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1,000 microg daily nasal hPTH(1-34) spray for 3 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Daily supplements of 300 mg calcium and 200 IU vitamin D(3)
Number of subjects: 90
Study: 14517200

Group type: EXPERIMENTAL
Intervention: Sirolimus (10 mg oral dose) alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sirolimus (10 mg oral dose) administered 4 hours after CsA (300 mg oral dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cyclosporine (300 mg oral dose) alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sirolimus (10 mg oral dose)
Number of subjects: 21
Study: 11225965

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9200296

Group type: EXPERIMENTAL
Intervention: Surgery (cholecystectomy)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Observation (conservative treatment)
Number of subjects: 501
Study: 7827590

Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol (I3C) 400 mg/day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alpha-cellulose 20 g/day for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3402101

Group type: EXPERIMENTAL
Intervention: Cotton wool earplugs covered with petroleum jelly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water instillation (1 drop 0.05 ml, 2 drops 0.1 ml, or no water)
Number of subjects: 30
Study: 30008392

Group type: EXPERIMENTAL
Intervention: Goal-setting intervention with a focus on experiential goals
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Planning by stating intentions
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Attention to instrumental goals
Number of subjects: 556

Group type: COMPARATOR
Intervention: Repeated pairing of goals with the school meal
Number of subjects: 556
Study: 28526374

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (500,000 IU total over 5 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (250,000 IU total over 5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (both doses)
Number of subjects: 30
Study: 26232311

Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol-citrate-simethicone plus 2-day bisacodyl
Number of subjects: 400

Group type: COMPARATOR
Intervention: 4-L polyethylene glycol
Number of subjects: 400
Study: 24827127

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 2.0 mg/m² on day 1 with erlotinib 150 mg on days 2-16 (21-day regimen)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² on days 1 and 8 with erlotinib 150 mg on days 15-28 (28-day regimen)
Number of subjects: 123
Study: 22533456

Group type: EXPERIMENTAL
Intervention: Website usability testing with 21 patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Website evaluation by 103 patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Internet access among participants
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Age as a differentiating factor
Number of subjects: 103
Study: 20102890

Group type: EXPERIMENTAL
Intervention: Quinapril 40 mg/day orally (n = 43)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (n = 43)
Number of subjects: 86
Study: 18600119

Group type: EXPERIMENTAL
Intervention: Effective nursing interventions conducted daily for 45 to 60 minutes after the 7th to 10th day of chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine nursing interventions
Number of subjects: 60
Study: 15999048

Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin III (75 U/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 52
Study: 12177105

Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (5.0 mg/kg/d for 10 days) administered before each radiation treatment
Number of subjects: 25
Study: 10615219

Group type: EXPERIMENTAL
Intervention: High-MUFA diet (38% energy as fat, 18% as MUFA, 10% as saturated fatty acids)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-MUFA diet and Control diet
Number of subjects: 53
Study: 9411973

Group type: EXPERIMENTAL
Intervention: Use of the term 'smoker's lung' in communication with patients (intervention group, n = 25)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional terminology used in communication (control group, n = 31)
Number of subjects: 56
Study: 1472933

Group type: EXPERIMENTAL
Intervention: Cytarabine and lomustine (experimental arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Busulfan (conventional treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (hydrea or busulfan)
Number of subjects: 0
Study: 4028625

Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system of scopolamine (TTS-S)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Transdermal placebo (TD-P)
Number of subjects: 49
Study: 31326951

Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes at an average speed of 3 km/h on the last night before surgery.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no walking on the last night before surgery).
Number of subjects: 85
Study: 29404931

Group type: EXPERIMENTAL
Intervention: Trial formulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 20
Study: 27966507

Group type: EXPERIMENTAL
Intervention: Pre-etching with 37% orthophosphoric acid for 10 seconds (Group 2a)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pre-etching with 37% orthophosphoric acid for 30 seconds (Group 2b)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pre-etching with 37% orthophosphoric acid for 60 seconds (Group 2c)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group without pre-etching (Group 1)
Number of subjects: 200
Study: 24779438

Group type: EXPERIMENTAL
Intervention: ADL intervention performed by occupational therapists
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard treatment and care (control group)
Number of subjects: 118
Study: 22466981

Group type: EXPERIMENTAL
Intervention: Vein collar at distal anastomosis of PTFE-grafts
Number of subjects: 345
Study: 19833379

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 18929013

Group type: EXPERIMENTAL
Intervention: Neutral functional realignment orthosis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard rehabilitation program without orthosis
Number of subjects: 30
Study: 15640477

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg calcium carbonate/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 96
Study: 12047486

Group type: EXPERIMENTAL
Intervention: Low dose of ayahuasca (0.6 mg DMT kg(‐1) body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High dose of ayahuasca (0.85 mg DMT kg(‐1) body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10076615

Group type: EXPERIMENTAL
Intervention: Hepatectomy with hyperthermochemohypoxic isolated liver perfusion (HILP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hepatectomy with HILP
Number of subjects: 16
Study: 7738505

Group type: EXPERIMENTAL
Intervention: Participants asked to view the text situation from the point of view of the protagonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants in Experiment 1
Number of subjects: 0
Study: 8479131

Group type: EXPERIMENTAL
Intervention: Ketoacid supplement (KA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amino acid supplement (AA)
Number of subjects: 16
Study: 3903069

Group type: EXPERIMENTAL
Intervention: Dipyridamole administration
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group (no dipyridamole)
Number of subjects: 348
Study: 31597315

Group type: EXPERIMENTAL
Intervention: Quercetin (CM+Q group), administered orally for 3-5 days before catheterization.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contrast media only (CM group).
Number of subjects: 0
Study: 29678155

Group type: EXPERIMENTAL
Intervention: Healthy Active Peaceful Playgrounds for Youth (HAPPY) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 27131182

Group type: EXPERIMENTAL
Intervention: Carrying one 1.5kg bag in each hand
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carrying one 3kg bag in each hand
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carrying one 1.5kg bag in preferred hand
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carrying one 3kg bag in preferred hand
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carrying no bags
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carrying bags (any load distribution)
Number of subjects: 9
Study: 25362220

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3 cycles of 5-minute ischemia in the right arm
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group - received 1000 mL of normal saline before CAA
Number of subjects: 96
Study: 22395527

Group type: EXPERIMENTAL
Intervention: Lurasidone (40-120 mg)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Risperidone (2-6 mg)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 629
Study: 20346209

Group type: EXPERIMENTAL
Intervention: Sapylin + mitomycin C
Number of subjects: 79

Group type: COMPARATOR
Intervention: Mitomycin C alone
Number of subjects: 79
Study: 18625622

Group type: EXPERIMENTAL
Intervention: 8 mg/kg tocilizumab
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: 4 mg/kg tocilizumab
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 499
Study: 15664873

Group type: EXPERIMENTAL
Intervention: No dressing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Thin adhesive dressing (tegaderm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bulky dressing (wool and crepe)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (other knee)
Number of subjects: 18
Study: 12028251

Group type: EXPERIMENTAL
Intervention: Fear of falling
Number of subjects: 1500
Study: 10524421

Group type: EXPERIMENTAL
Intervention: Boost of 16 Gy following whole-breast irradiation of 50 Gy
Number of subjects: 5318

Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5318

Group type: EXPERIMENTAL
Intervention: Panel evaluation
Number of subjects: 5318

Group type: EXPERIMENTAL
Intervention: Digitizer measurements
Number of subjects: 5318

Group type: EXPERIMENTAL
Intervention: Panel evaluation and digitizer measurements
Number of subjects: 5318
Study: 7739706

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg per day
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg per day
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 1962901

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily according to body weight classes (55 to 65 Factor‐Xa inhibitory U/kg) for 14 days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin)
Number of subjects: 103
Study: 116298

Group type: EXPERIMENTAL
Intervention: Naloxone (20 mg IV)
Number of subjects: 0
Study: 30853359

Group type: EXPERIMENTAL
Intervention: Vaccinated women
Number of subjects: 14153

Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 14153
Study: 28422122

Group type: EXPERIMENTAL
Intervention: Concept IMF (experimental)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control IMF (current)
Number of subjects: 29
Study: 25722948

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: COMT met alleles interaction
Number of subjects: 187
Study: 23988413

Group type: EXPERIMENTAL
Intervention: Web-based advance care planning tool
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control website
Number of subjects: 53
Study: 21200337

Group type: EXPERIMENTAL
Intervention: PDA with daily tailored feedback message (PDA + FB)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PA self-monitoring
Number of subjects: 210

Group type: COMPARATOR
Intervention: All three arms (PR, PDA, PDA + FB)
Number of subjects: 210
Study: 19276559

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 17905915

Group type: EXPERIMENTAL
Intervention: Syntactic-semantic therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Semantic therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 27
Study: 15115449

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 11678746

Group type: EXPERIMENTAL
Intervention: Endotoxin levels in urine after prostatic massage
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Endotoxin concentration in EPS
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Endotoxin level in urine after massage
Number of subjects: 88
Study: 9576161

Group type: EXPERIMENTAL
Intervention: Device I (oscillometric detection)
Number of subjects: 120

Group type: COMPARATOR
Intervention: All devices tested
Number of subjects: 120

Group type: COMPARATOR
Intervention: Noninvasive measurement by oscillometry with stepped deflation
Number of subjects: 120
Study: 8017999

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled data from first five randomized trials
Number of subjects: 0
Study: 2828071

Group type: EXPERIMENTAL
Intervention: vindesine and cisplatinum
Number of subjects: 48

Group type: COMPARATOR
Intervention: vindesine and methotrexate
Number of subjects: 48
Study: 31563507

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0
Study: 30017699

Group type: EXPERIMENTAL
Intervention: M1 a‐tDCS with postural training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bilateral cerebellar a‐tDCS with postural training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham a‐tDCS with postural training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Postural training alone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cerebellar a‐tDCS alone
Number of subjects: 65
Study: 28949895

Group type: EXPERIMENTAL
Intervention: Enhanced arm (phone-based intervention)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Basic arm (results simply distributed)
Number of subjects: 41
Study: 26673292

Group type: EXPERIMENTAL
Intervention: Gene engineering technologies of angiogenesis stimulation as an independent method of treatment in comprehensive conservative therapy (80 patients)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Gene engineering technologies of angiogenesis stimulation as comprehensive treatment in combination with revascularizing operations (80 patients)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Gene engineering technologies of angiogenesis stimulation
Number of subjects: 160
Study: 23587630

Group type: EXPERIMENTAL
Intervention: Compact catheter
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard hydrophilic coated catheters
Number of subjects: 125
Study: 20729532

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study: 18582373

Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 16
Study: 17099421

Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography (MRE) using bSSFP sequence
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Follow-up studies
Number of subjects: 14
Study: 12808401

Group type: EXPERIMENTAL
Intervention: Nonpreserved lubricants, topical steroidal and nonsteroidal anti-inflammatory agents, punctal plugs for aqueous-deficient dry eye, mechanical removal of filaments, hypertonic saline, mucolytic agents, and bandage contact lenses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative ocular surface management strategies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternate medications or additional measures to manage the tear film and ocular surface.
Number of subjects: 0
Study: 10954213

Group type: EXPERIMENTAL
Intervention: Emollients (4 different types applied thickly on half of the face)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: White petrolatum (one of the emollients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Untreated control (the other half of the face without emollients)
Number of subjects: 46
Study: 8796369

Group type: EXPERIMENTAL
Intervention: Lp(a) fractions containing mainly small apo(a) isoforms (either B or S1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lp(a) fractions containing mainly high molecular mass isoforms (either S3 or S4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in Kd as a function of the relative content in isoforms of high molecular mass
Number of subjects: 0
Study: 1610631

Group type: EXPERIMENTAL
Intervention: Demand top-ups of 0.25% plain bupivacaine 10 ml
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.125% plain bupivacaine 10 ml h‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Patient-controlled extradural analgesia (PCEA) delivering 3-ml boluses of 0.25% bupivacaine
Number of subjects: 3
Study: 3968329

Group type: EXPERIMENTAL
Intervention: Bitolterol aerosol (three sprays, 1.11 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Albuterol aerosol (two sprays, 180 mcg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bitolterol aerosol
Number of subjects: 120
Study: 30801888

Group type: EXPERIMENTAL
Intervention: Male ophthalmologists
Number of subjects: 282

Group type: COMPARATOR
Intervention: Female ophthalmologists
Number of subjects: 282
Study: 28786197

Group type: EXPERIMENTAL
Intervention: Chinese Health Improvement Profile (CHIP) intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 137
Study: 27444660

Group type: EXPERIMENTAL
Intervention: ONO‐6950 (200 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Montelukast (10 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24534331

Group type: EXPERIMENTAL
Intervention: Socioeconomic status measures (education, household expenditures, household assets, subjective wealth, father's education)
Number of subjects: 3993

Group type: COMPARATOR
Intervention: General population across all SES groups
Number of subjects: 3993
Study: 22160854

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily plus TMZ 150 mg/m(2)/day for 5 days every 28 days (NEIAEDs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Everolimus (various doses) plus TMZ (150 mg/m(2)/day) (EIAEDs)
Number of subjects: 32
Study: 21055801

Group type: EXPERIMENTAL
Intervention: 1 μg/day paricalcitol
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 2 μg/day paricalcitol
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 17656129

Group type: EXPERIMENTAL
Intervention: Conventional technique
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bone-condensing technique
Number of subjects: 14
Study: 16583596

Group type: EXPERIMENTAL
Intervention: Colgate Total dentifrice (CTD)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Colgate Cavity Protection (CCP)
Number of subjects: 11
Study: 11918909

Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 162

Group type: COMPARATOR
Intervention: Alteplase plus abciximab
Number of subjects: 162
Study: 10557953

Group type: EXPERIMENTAL
Intervention: Very low doses of estrogen combined with vitamin D and calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy with very low doses of estrogen
Number of subjects: 0
Study: 8556189

Group type: EXPERIMENTAL
Intervention: Dofetilide (0.1 to 8.0 ng/mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1683403

Group type: EXPERIMENTAL
Intervention: Cabergoline 1.0 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.75 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 7137550

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Halothane and Enflurane
Number of subjects: 100
Study: 31685833

Group type: EXPERIMENTAL
Intervention: hTERC gene examination using fluorescence in situ hybridization (FISH)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: HR‐HPV infection
Number of subjects: 1200
Study: 28975239

Group type: EXPERIMENTAL
Intervention: Muscle-sparing technique (n=11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Muscle-cutting technique (n=8)
Number of subjects: 19
Study: 26995371

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) reported after hospital discharge
Number of subjects: 48118

Group type: EXPERIMENTAL
Intervention: Serious adverse events (SAEs) reported after hospital discharge
Number of subjects: 48118

Group type: EXPERIMENTAL
Intervention: Distribution of nonserious AEs across system organ classes
Number of subjects: 48118

Group type: EXPERIMENTAL
Intervention: Predictors of more SAEs
Number of subjects: 48118

Group type: EXPERIMENTAL
Intervention: Predictors of fewer SAEs
Number of subjects: 48118